Context: One of the most prevalent comorbidities in the ART era is Human immunodeficiency virus-related neurocognitive disorder. The prevalence of HIV-Associated Neurocognitive Disorder is said to vary from 20% to 88%. A promising approach to treating and preventing neurocognitive problems in Human immunodeficiency virus-positive individuals is the encapsulation of nanosized antiretrovirals in various polymers, which can improve their absorption into the central nervous system and other latent viral reservoirs.Primary text: The term HAND refers to the range of neurocognitive impairments associated with Human immunodeficiency virus infection. Declining brain activity leads to neurocognitive issues.Although ART has been utilised to improve cognitive function and reverse the course of the disease, hand diseases presently lack a distinct form of therapy. Adsorbed onto or incorporated into a polymer matrix, polymeric nanoformulations are solid colloidal systems containing active therapeutic ingredients. Particle sizes for these substances range from 1 to 1,000 nm. An array of hydrophilic and hydrophobic medications, vaccines, peptides, and biological macromolecules may be delivered in a controlled manner using polymeric nanoformulations. Conclusion: When PNPs are actively targeted, promising outcomes have been shown in preclinical research and, in certain situations, early clinical trials. Since polymeric nanoformulations have the potential to eliminate latent viral reservoirs, more Study is needed on their use in HAND treatment. Furthermore, new antiviral drugs that are safe, effective, and simple to use for both adult and pediatric HIV+ patients are required.